View Older Stories View More Recent Stories

May 15, 2020 08:55AM Bristol-Myers Squibb (BMY) Announces FDA Approves ts Pomalyst for AIDS-Related and HIV-Negative Kaposi Sarcoma
May 15, 2020 08:53AM U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma
May 13, 2020 05:08PM Bristol-Myers Squibb (BMY) Opdivo Plus Yervoy with Limited Chemotherapy Significantly Improves Overall Survival vs. Chemotherapy Alone for Patients with First-Line Metastatic NSCLC in CheckMate -9LA S
May 13, 2020 05:07PM Bristol-Myers Squibb (BMY) Three-Year Data from CheckMate -227 Confirm Durable, Long-Term Survival Benefit for Opdivo Plus Yervoy vs. Chemotherapy in Metastatic First-Line NSCLC
May 13, 2020 05:06PM Bristol Myers Squibb (BMY) and bluebird bio (BLUE) to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in R/R Multiple Myeloma Patients at ASCO20
May 13, 2020 05:00PM Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20
May 13, 2020 05:00PM Three-Year Data from CheckMate -227 Confirm Durable, Long-Term Survival Benefit for Opdivo (nivolumab) Plus Yervoy (ipilimumab) vs. Chemotherapy in Metastatic First-Line Non-Small Cell Lung Cancer Pat
May 13, 2020 05:00PM Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Limited Chemotherapy Significantly Improves Overall Survival vs. Chemotherapy Alone for Patients with First-Line Metastatic Non-Small Cell Lung Cancer
May 13, 2020 07:00AM Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Provide Regulatory Update on Idecabtagene Vicleucel for Treatment of Patients with MM, BLA Requires Further Detail
May 13, 2020 06:59AM Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma
May 12, 2020 07:07AM GRYT Health and Bristol Myers Squibb Team Up to Launch COVID Advocacy Exchange for Patient Advocates
May 12, 2020 06:59AM Bristol Myers Squibb to Take Part in the UBS Virtual Global Healthcare Conference
May 12, 2020 06:58AM GRYT Health and Bristol Myers Squibb Team Up to Launch COVID Advocacy Exchange for Patient Advocates
May 11, 2020 06:59AM Bristol Myers Squibb Research at ASCO Demonstrates Diverse Approaches in Treating Cancer to Improve Outcomes for Patients
May 7, 2020 06:59AM Bristol Myers Squibb Reports Strong First Quarter 2020 Financial Results
May 6, 2020 07:00AM Bristol-Myers Squibb (BMY) Provides Update on BLA for Lisocabtagene Maraleucel
May 6, 2020 06:59AM Bristol Myers Squibb Provides Update on Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel)
May 1, 2020 07:00AM Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review its Application for CC-486 for Maintenance Treatment of Adult Patients in Remission with AML
May 1, 2020 06:59AM U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Application for CC-486 for Maintenance Treatment of Adult Patients in Remission with Acute Myeloid Leukemia
Apr 30, 2020 05:13PM Bristol (BMY) and Acceleron (XLRN) Announce Reblozyl Receives Positive CHMP Opinion for Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
Apr 30, 2020 04:16PM Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes
Apr 23, 2020 01:01AM Press Release Biocartis Group NV: Biocartis Q1 2020 Business Update
Apr 20, 2020 07:10AM Bristol Myers Squibb (BMY), Exelixis (EXEL) Announce Positive Topline Results from Phase 3 CheckMate -9ER Trial Evaluating Opdivo in Combination with CABOMETYX in Previously Untreated RCC
Apr 20, 2020 06:59AM Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural
Apr 20, 2020 06:59AM Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previous
Apr 14, 2020 04:16PM Bristol Myers Squibb Announces Virtual 2020 Annual Meeting of Shareholders
Apr 14, 2020 07:35AM Intensity Therapeutics Signs Clinical Collaboration Agreement with Bristol Myers Squibb for Advanced Solid Tumors
Apr 8, 2020 06:59AM Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer
Apr 7, 2020 06:59AM Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S.
Apr 3, 2020 05:08PM U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt), the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS
Mar 31, 2020 07:00AM Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Announce Submission of BLA for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel to FDA
Mar 31, 2020 06:59AM Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA
Mar 27, 2020 11:06AM Bristol Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA for Treatment of Adult Patients with RRMS with Active Disease
Mar 27, 2020 11:05AM Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of ZEPOSIA® (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease
Mar 26, 2020 07:01AM Bristol-Myers Squibb (BMY) and Acceleron (XLRN) Announces NEJM Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl in Adult Patients With Beta Thalassemia
Mar 26, 2020 06:59AM New England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia
Mar 26, 2020 06:58AM Bristol Myers Squibb to Announce Results for First Quarter 2020 on May 7, 2020
Mar 26, 2020 06:31AM Bristol-Myers Squibb (BMY) Confirms FDA Approved its ZEPOSIA, a New Oral Treatment for Relapsing Forms of MS
Mar 26, 2020 06:30AM U.S. Food and Drug Administration Approves Bristol Myers Squibb’s ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis
Mar 23, 2020 06:59AM Bristol-Myers Squibb Postpones April 2, 2020 Investor Day
Mar 18, 2020 06:59AM Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development
Mar 11, 2020 06:59AM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for Patients with Hepatocellular Carcinoma (HCC) Previously Treated with Sorafenib
Mar 9, 2020 07:00AM Bristol-Myers Squibb (BMY) Highlights Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) & Dexamethasone
Mar 9, 2020 06:59AM Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple M
Mar 5, 2020 01:02AM Press release Biocartis Group NV: BIOCARTIS ANNOUNCES 2019 RESULTS AND 2020 OUTLOOK
Mar 5, 2020 01:01AM Biocartis Announces New Immuno-Oncology Project with Bristol-Myers Squibb Aimed at Registration of Idylla™ MSI test in China
Mar 3, 2020 05:31PM Voluntis and Bristol-Myers Squibb (BMY) to Co-Develop Digital Therapeutics for Oncology
Mar 3, 2020 05:30PM Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology
Mar 2, 2020 04:16PM Bristol‑Myers Squibb Announces Dividend Increase
Mar 2, 2020 04:16PM CORRECTING and REPLACING Bristol‑Myers Squibb Announces Dividend
View More Recent Stories View Older Stories